Sign Up
Stories
AI Partnerships Drive Drug Discovery
Share
ADvantage Therapeutics Appoints Professo...
AI Advancements in Drug Discovery
AI's Healing Potential and Terrorism Cha...
AI Enhances Animal Behavior Studies
AI Revolutionizes Healthcare Diagnosis
AI-Driven Telehealth: Balancing Innovati...
Overview
API
Isomorphic Labs, a DeepMind spin-out, partners with Eli Lilly and Novartis for $3 billion in drug discovery deals. The collaboration aims to apply AI to discover new medications, leveraging DeepMind's AI technology for protein structure predictions and therapeutic drug design.
Ask a question
How might these AI-driven drug discovery collaborations impact the pharmaceutical industry and patient outcomes?
In what ways could these partnerships influence the future of AI research and its applications in healthcare?
What ethical considerations arise from the use of AI in drug discovery, and how are they being addressed?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Oct 2023
Nov 2023
Dec 2023
Coverage